Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) Director Bruce Cozadd sold 6,000 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $215.84, for a total transaction of $1,295,040.00. Following the completion of the sale, the director owned 339,875 shares of the company's stock, valued at $73,358,620. This trade represents a 1.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jazz Pharmaceuticals Stock Performance
NASDAQ:JAZZ opened at $234.66 on Thursday. The company has a market cap of $15.06 billion, a P/E ratio of 79.82, a P/E/G ratio of 0.46 and a beta of 0.38. Jazz Pharmaceuticals PLC has a twelve month low of $128.80 and a twelve month high of $266.38. The company's 50-day moving average price is $230.15 and its 200-day moving average price is $217.11. The company has a current ratio of 1.82, a quick ratio of 1.58 and a debt-to-equity ratio of 1.09.
Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.03) by $0.15. The company had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $1.21 billion. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. Jazz Pharmaceuticals's revenue was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $8.13 EPS. On average, sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 10.84 earnings per share for the current fiscal year.
Analyst Ratings Changes
JAZZ has been the subject of a number of analyst reports. Stifel Nicolaus set a $275.00 price target on Jazz Pharmaceuticals in a research report on Tuesday, August 4th. UBS Group lifted their price objective on Jazz Pharmaceuticals from $315.00 to $337.00 and gave the stock a "buy" rating in a research report on Friday, September 11th. TD Cowen boosted their price objective on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the stock a "buy" rating in a research note on Tuesday, August 4th. Weiss Ratings lowered Jazz Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Wednesday, October 28th. Finally, The Goldman Sachs Group assumed coverage on Jazz Pharmaceuticals in a report on Thursday, September 24th. They issued a "buy" rating and a $337.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $293.45.
Check Out Our Latest Stock Report on Jazz Pharmaceuticals
Hedge Funds Weigh In On Jazz Pharmaceuticals
Institutional investors and hedge funds have recently bought and sold shares of the company. Lido Advisors LLC increased its holdings in shares of Jazz Pharmaceuticals by 5.2% during the 3rd quarter. Lido Advisors LLC now owns 2,644 shares of the specialty pharmaceutical company's stock worth $612,000 after buying an additional 131 shares during the last quarter. Keybank National Association OH raised its position in shares of Jazz Pharmaceuticals by 0.6% during the 3rd quarter. Keybank National Association OH now owns 10,141 shares of the specialty pharmaceutical company's stock valued at $2,348,000 after buying an additional 57 shares during the period. Csenge Advisory Group raised its position in shares of Jazz Pharmaceuticals by 4.1% during the 3rd quarter. Csenge Advisory Group now owns 5,242 shares of the specialty pharmaceutical company's stock valued at $1,214,000 after buying an additional 205 shares during the period. Penn Capital Management Company LLC acquired a new position in Jazz Pharmaceuticals in the third quarter valued at approximately $1,009,000. Finally, AEGON ASSET MANAGEMENT UK Plc acquired a new position in Jazz Pharmaceuticals in the third quarter valued at approximately $2,007,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.
Jazz Pharmaceuticals News Roundup
Here are the key news stories impacting Jazz Pharmaceuticals this week:
- Positive Sentiment: Jazz beat Q3 revenue and earnings expectations, with growth in oncology and rare sleep products cited as drivers. The company raised its 2026 revenue outlook to roughly $4.78 billion–$4.85 billion, above the prior consensus near $4.7 billion. Q3 earnings and outlook
- Positive Sentiment: The company announced a $500 million share buyback, which may support shareholder returns and provide demand for the stock. Share buyback announcement
- Positive Sentiment: Several analysts raised their price targets and maintained bullish ratings after the results, including JPMorgan, Morgan Stanley, RBC and Barclays. Analyst insights
- Neutral Sentiment: Director Bruce Cozadd sold 6,000 shares under a pre-arranged Rule 10b5-1 plan, reducing his position by 1.73%; he retained 339,875 shares after the sale. SEC filing
- Negative Sentiment: Some coverage cautioned that slowing growth and an Actiq-related charge could temper the positive effect of the earnings beat and improved guidance. Earnings outlook risks
Jazz Pharmaceuticals Company Profile
(
Get Free Report)
Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.
Jazz's sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
